Activated macrophage targetable drug carrier for treatment of atherosclerosis and methods of preparing the same
Provided is a drug carrier for treatment of atherosclerosis including a biocompatible amphipathic polymer including a macrophage ligand polymer and a hydrophobic substance, and a hydrophobic drug.
1. A drug carrier for treatment of atherosclerosis, the drug carrier consisting of:
an amphipathic polymer consisting of a hydrophilic polymer, a hydrophobic substance, and a target ligand recognizing a mannose receptor of a macrophage; and
a hydrophobic drug for treatment of atherosclerosis,
wherein the hydrophilic polymer is a chitosan derivative, and
the hydrophobic substance is a cholesterol derivative.
2. The drug carrier of claim 1 , wherein the target ligand recognizing the mannose receptor of the macrophage includes: mannose amine or mannose phosphate.
3. The drug carrier of claim 1 , wherein the hydrophobic drug for treatment of atherosclerosis includes at least one selected from the group consisting of statin drugs, PPAR-gamma agonist drugs, DPP-4 inhibitor drugs, angiotensin converting enzyme inhibitor drugs, angiotensin II receptor blockers, PCSK9 inhibitors, and antioxidants.
4. A method of preparing the drug carrier of claim 1 for treatment of atherosclerosis, the method comprising preparing the amphipathic polymer; forming nanoparticles by self-assembling the amphipathic polymer and impregnating the hydrophobic drug in the nanoparticles.
5. A drug carrier for treatment of atherosclerosis, the drug carrier consisting of:
a first amphipathic polymer including a macrophage ligand polymer and a hydrophobic substance;
a second amphipathic polymer consisting of a hydrophilic polymer, said hydrophobic substance, and a target ligand recognizing a mannose receptor of a macrophage; and
a hydrophobic drug for treatment of atherosclerosis,
wherein the macrophage ligand polymer is a dextran derivative,
the hydrophobic substance is a cholesterol derivative, and
the hydrophilic polymer is a chitosan derivative.
6. A method for preparing the drug carrier of claim 5 , the method comprising: preparing the first amphipathic polymer; preparing the second amphipathic polymer; forming nanoparticles by self-assembling the amphipathic polymers; and impregnating the hydrophobic drug in the nanoparticles.
7. A drug carrier for treatment of atherosclerosis, the drug carrier consisting of:
a first amphipathic polymer including a macrophage ligand polymer, a hydrophobic substance, and a target ligand recognizing a mannose receptor of a macrophage;
a second amphipathic polymer consisting of a hydrophilic polymer, a hydrophobic substance, and a target ligand recognizing a mannose receptor of a macrophage; and
a hydrophobic drug for treatment of atherosclerosis,
wherein the macrophage ligand polymer is a dextran derivative,
the hydrophobic substance is a cholesterol derivative, and
the hydrophilic polymer is a chitosan derivative.